Manus Neurodynamica is revolutionising health care management by developing and patenting neuroscience technologies that record recognised biomarkers of neuromotor impairments which can radically improve patient diagnosis and disease monitoring. Our disruptive technology has potential to be used across applications such as screening, rehabilitation and drug development and medicine optimisation, streamlining referrals, reducing costs and increasing the efficiency of specialist services. We are looking for interested researchers, clinicians and practitioners to collaborate in situ assessment and testing of the NeuroMotor pen, as well as investors for the further development of our projects in the EU and US. Our principal product, the NeuroMotor Pen, is a non-invasive, patented medical device that offers earlier-diagnosis and monitoring of neuromotor disorders. Combined with analytical software, the NeuroMotor Pen, processes a patients’ movement parameters, by analysing minute limb and hand motion to quantify fine motor skills and motion features. These motion features are used as "biomarkers" to provide objective information to clinicians about movement abnormalities and this innovative technology can streamline secondary care referrals, reduce costs and increase the efficiency of specialist neuromotor services.